Results 1 to 10 of about 41,447 (182)

A label free chemoproteomic-based platform to disclose cannabidiol molecular mechanism of action on chronic myelogenous leukemia cancer cells [PDF]

Heliyon
The discovery of the interactome of cannabidiol (CBD), a non-psychoactive cannabinoid from Cannabis sativa L., has been here performed on chronic myelogenous leukemia cancer cells, using an optimized chemo-proteomic stage, which links Drug Affinity ...
Sara Ceccacci, Lorenzo Corsi, Lucio Spinelli, Clarissa Caroli, Matilde Marani, Lisa Anceschi, Matteo Mozzicafreddo, Federica Pellati, Maria Chiara Monti   +8 more
doaj   +2 more sources

Granulocytic Sarcoma with Compressive Myelopathy: A Rare Presentation of Chronic Myelogenous Leukemia [PDF]

Journal of Clinical and Diagnostic Research, 2014
Granulocytic sarcoma occurs most commonly in acute myelogenous leukemia. The appearance of granulocytic sarcoma in chronic myelogenous leukemia signals accelerated phase/ blast transformation.
Abhijeet P. Ganapule, Auro Viswabandya, Anita Jasper, Palak Patel, Gautami Kokil   +4 more
doaj   +1 more source

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia

Clinical Case Reports, 2021
Gastrointestinal manifestations of leukemias have been well recognized. Typically, acute leukemias cause typhlitis or appendicitis more commonly than chronic leukemias.
Rita Ahmad, Elrazi Ali, Lina Okar, Orwa Elaiwy, Mohamed Abdelrazek, Yahya Mulikandathil, Mohamed Yassin   +6 more
doaj   +1 more source

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Haematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani   +9 more
doaj   +1 more source

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature

Indian Journal of Pathology and Microbiology, 2013
Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar, Jasmina Ahluwalia, Pankaj Malhotra, Man Updesh Singh Sachdeva   +3 more
doaj   +1 more source

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

Case Reports in Cardiology, 2018
Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia.
Pradyumna Agasthi, Hemalatha Narayanasamy, Dan Sorajja, James Slack, Farouk Mookadam   +4 more
doaj   +1 more source

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Haematologica, 2013
The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed.
Franck E. Nicolini, Amr R. Ibrahim, Simona Soverini, Giovanni Martinelli, Martin C. Müller, Andreas Hochhaus, Inge H. Dufva, Dong-Wook Kim, Jorge Cortes, Michael J. Mauro, Charles Chuah, Hélène Labussière, Stéphane Morisset, Catherine Roche-Lestienne, Eric Lippert, Sandrine Hayette, Senaka Peter, Wei Zhou, Véronique Maguer-Satta, Mauricette Michallet, John Goldman, Jane F. Apperley, François-Xavier Mahon, David Marin, Gabriel Etienne   +24 more
doaj   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Chloroma of the testis in a patient with a history of acute myeloid leukemia

Journal of Research in Medical Sciences, 2017
Chloroma, or granulocytic sarcoma, is a rare extramedullary solid hematologic cancer, found concomitant with acute myeloid leukemia. It is infrequently associated with other myeloproliferative disorders or chronic myelogenous leukemia.
Mohammad Hossein Sanei, Matin Shariati
doaj   +1 more source

Usefulness of Terminal Deoxynucleotidyl Transferase as Prognosticator in Leukemia Patients

The International Journal of Biological Markers, 1993
Peripheral blood samples from 55 previously untreated leukemia patients (33 males, 22 females) were analysed for terminal deoxynucleotidyl transferase (TdT) activity.
J.M. Bhatavdekar, S.N. Trivedi, H.H. Vora, S.N. Shukla   +3 more
doaj   +1 more source